Oximio, South Africa, attains an additional resolution to SAHPRA Licence, Paving the Way for Medical Cannabis Innovation

Thursday, October 19, 2023 by Oximio

The attainment of the licence places Oximio, South Africa, as a premier distributor for medical cannabis products for commercial or clinical trial purposes from Africa, extending the company’s reach to support the international market.

Mykola Nikolaiev, CEO, Oximio, says “this marks a significant turning point in our operations, exemplifying our commitment to supporting the use of medical cannabis in clinical trials whilst underscoring our commitment to maintaining the highest standards of quality and care.”

 


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.